Quarterly ResultAug 11, 2026, 04:49 PM
Maze Therapeutics Q2 Net Loss $44.7M; $495M Cash, Runway into 2029
AI Summary
Maze Therapeutics, Inc. reported a net loss of $44.7 million ($0.76 per share) for the second quarter ended June 30, 2026. The company maintained a strong balance sheet with $494.9 million in cash, cash equivalents, and marketable securities, extending its expected cash runway into 2029. Key operational updates include MZE829 Phase 2 HORIZON trial data expected in late 2026 or early 2027, and the initiation of the MZE782 Phase 2 CIPheR trial for PKU with topline data anticipated in 2027.
Key Highlights
- Cash, cash equivalents, and marketable securities were $494.9 million as of June 30, 2026.
- Company expects cash runway into 2029 based on current business plan.
- Net loss for Q2 2026 was $44.7 million, or $0.76 per share.
- Research & Development expenses for Q2 2026 were $34.9 million.
- MZE829 HORIZON trial data expected late 2026 or early 2027.
- MZE782 CIPheR trial initiated for PKU; topline data expected in 2027.
- MZE782 CKD Phase 2 trial on track for H1 2027 initiation.
Price Impact
More from MAZE